N
NVO
Novo-Nordisk A/S
$38.12
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of Novo-Nordisk A/S in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
$0.38
Yield
1.00%
EPS
$26.18
P/E
9.6
Data as of Oct 1
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Upcoming events
Quarterly earnings
Expected EPS: $5.07
Nov 4
Posts
No posts about NVO yet.
About Novo-Nordisk A/S
Novo Nordisk is a Danish pharmaceutical company best known for its diabetes and weight-loss drugs, including Ozempic, Wegovy, and Rybelsus. It makes most of its money selling these GLP-1 injections and pills, along with insulin and other treatments, to patients and health systems around the world. A smaller part of the business sells drugs for blood disorders like hemophilia and for growth-hormone conditions.